Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

BMC Infectious Diseases

Volumn 4, Issue , 2004, Pages

  Blaney Jr , Joseph E ^a   Hanson, Christopher T ^a   Hanley, Kathryn A ^a   Murphy, Brian R ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DENGUE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOTIDE; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

3' UNTRANSLATED REGION; AEDES; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; GENE DELETION; GENETIC ENGINEERING; GENOTYPE; HEPATOMA CELL; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOSQUITO; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTECTION; RHESUS MONKEY; SCID MOUSE; VIREMIA; VIRUS ATTENUATION; VIRUS GENE; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TYPING; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CERCOPITHECUS; CLASSIFICATION; ECONOMICS; GENETICS; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE MUTANT; MUTATION; STANDARD; TUMOR CELL CULTURE; VERO CELL; VIROLOGY; VIRUS CULTURE;

AEDES; ANIMALS; ANTIBODIES, VIRAL; CARCINOMA, HEPATOCELLULAR; CELL TRANSPLANTATION; CERCOPITHECUS AETHIOPS; CULICIDAE; DENGUE; DENGUE VIRUS; GENOTYPE; HUMANS; LIVER NEOPLASMS; MACACA MULATTA; MICE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; SERIAL PASSAGE; TUMOR CELLS, CULTURED; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VIRAL VACCINES; VIREMIA; VIRUS REPLICATION;

EID: 10144249661     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-4-39     Document Type: Article

References (32)

1. Almond J, Clemens J, Engers H, Halstead S, Khiem H, Pablos-Mendez A, Pervikov Y, Tram T: Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City, VietNam. Vaccine 2002, 20:3043-3046.
2. Gubler DJ: Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11:480-496.
3. Rothman AL, Ennis FA: Immunopathogenesis of dengue hemorrhagic fever. Virology 1999, 257:1-6.
4. Morens DM: Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994 19: 00-512.
5. Monath TP: Yellow fever. Vaccines 3rd edition. Edited by: Plotkin S A and Orenstein W A. Philadelphia, W.B. Saunders Co.; 1999:815-879.
6. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke C. H., Jr., Innis BL: Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69:24-31.
7. Blaney J. E., Jr., Johnson DH, Firestone CY, Hanson CT, Murphy BR, Whitehead SS: Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mic. J Virol 2001,75: 731-9740.
8. Markoff L, Pang X, Houng HS, Falgout B, Olsen R, Jones E, Polo S: Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 2002,76:3318-3328.
9. Bhamarapravati N, Sutee Y: Live attenuated tetravalent dengue vaccine. Vaccine2000, 18 Suppl 2:44-47.
10. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP: Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298:146-159.
11. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM: Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development. J Virol 2003, 77: 1436-11447.
12. Whitehead SS, Hanley KA, Blaney JE, Gilmore LE, Elkins WR, Murphy BR: Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003,21:4307-4316.
13. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS: Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 2001,65: 05-413.
14. Whitehead SS, Falgout B, Hanley KA, Blaney Jr. JE, Markoff L, Murphy BR: A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol2003, 77: 653-1657.
15. Blaney J. E., Jr., Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS: Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004, in press:
16. Blaney J. E., Jr., Johnson DH, Manipon GG, Firestone CY, Hanson CT, Murphy BR, Whitehead SS: Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002,300:125-139.
17. Hanley KA, Manlucu LR, Manipon GG, Hanson CT, Whitehead SS, Murphy BR, Blaney J. E., Jr.: Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 2004,22: 440-3448.
18. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke C. H., Jr.: Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003, 69:12-16.
19. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke C. H., Jr.: Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003,69:17-23.
20. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke Jr CH: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001,19:3179-3188.
21. Gubler DJ, Reed D, Rosen L, Hitchcock J. R., Jr.: Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 1978,27:581-589.
22. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR: A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001,65:414-419.
23. Blaney JE, Manipon GG, Firestone CY, Johnson DH, Hanson CT, Murphy BR, Whitehead SS: Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 2003, 21: 317-4327.
24. Armstrong PM, Rico-Hesse R: Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 2001,1: 59-168.
25. Armstrong PM, Rico-Hesse R: Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg 2003,68:539-544.
26. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002,66:264-272.
27. Watts DM, Porter KR, Putvatana P, Vasquez B, Calampa C, Hayes CG, Halstead SB: Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever [see comments]. Lancet 1999, 354:1431-1434.
28. Rico-Hesse R, Harrison LM, Salas RA, Tovar D, Nisalak A, Ramos C, Boshell J, de Mesa MT, Nogueira RM, da Rosa AT: Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997, 230:244-251.
29. Rico-Hesse R: Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990, 174: 79-493.
30. Gubler DJ, Clark GG: Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995, 1:55-57.
31. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de Chacon, Ramos C, Rico-Hesse R: Dengue virus structural differences that correlate with pathogenesis. J Virol 1999, 73: 738-4747.
32. Cologna R, Rico-Hesse R: American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003, 77:3929-3938.